CIK 0001781174
- Emerging growth company
Acrivon Therapeutics, Inc.
Sign in to watch- Ticker
- ACRV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 825125532
- Phone
- +1 617-207-8979
- Business address
- 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $37,028
- in 8 filings
Net −$37,028. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blume-Jensen Peter −$34K President and CEO sold 4% of stake
- Miller Mary −$2K Chief Legal Officer sold 1% of stake
- Devroe Eric −$911 Chief Operating Officer sold <1% of stake
- Gamelin Erick −$603 Chief Development Officer sold <1% of stake
- Peterson Katharine −$155 Chief Accounting Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-04 | Levy Adam D. Chief Financial Officer | Sale | −1,142 | $1.57 | $2K | 66,008 |
| 2026-05-18 | Levy Adam D. Chief Financial Officer | Grant or award | +46,167 | 67,150 | ||
| 2026-03-01 | Levy Adam D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +132,925 | 132,925 | ||
| 2026-01-14 | Levy Adam D. Chief Financial Officer | Purchase | +8,832 | $1.70 | $15K | 20,983 |
| 2025-08-01 | Levy Adam D. Chief Financial Officer | Shares withheld for taxes | −1,164 | $1.26 | $1K | 12,151 |
| 2025-04-01 | Levy Adam D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +35,209 | 35,209 |
Page 1 of 1 · 6 trades